openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) over potential Wrongdoing

An investigation on behalf of current long term investors in Actinium Pharmaceuticals, Inc. (NYSE: ATNM) shares.

An investigation on behalf of current long term investors in Actinium Pharmaceuticals, Inc. (NYSE: ATNM) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Actinium Pharmaceuticals, Inc.

Investors who are current long term investors in Actinium Pharmaceuticals, Inc. (NYSE: ATNM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NYSE: ATNM stocks follows a lawsuit filed against Actinium Pharmaceuticals, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NYSE: ATNM stocks, concerns whether certain Actinium Pharmaceuticals, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the Defendants failed to disclose that the Company's data from the Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate Sierra's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved, and that as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) over potential Wrongdoing here

News-ID: 4073049 • Views:

More Releases from Shareholders Foundation, Inc.

Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potential Wrongdoing
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced. Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for long term investors in
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ: FTNT)
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on October 07, 2025
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc. Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR)
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Actinium

Hematopoietic Stem Cell Transplantation Market to Reach New Heights in Growth by …
Hematopoietic Stem Cell Transplantation Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Sanofi, Actinium Pharma, Medexus Pharma, medac Pharma, Actinium Pharma The Hematopoietic Stem Cell Transplantation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hematopoietic Stem Cell Transplantation pipeline products will significantly revolutionize the Hematopoietic Stem Cell Transplantation market dynamics. DelveInsight's "Hematopoietic Stem
How Mobile Technology is Influencing the Actinium Isotope Market
Actinium Isotope Market size was valued at USD 1.2 Billion in 2024 and is forecasted to grow at a CAGR of 8.7% from 2026 to 2033, reaching USD 2.5 Billion by 2033. Actinium Isotope Market Future Scope The Actinium Isotope Market was valued at approximately USD 15 million in 2022, with a compound annual growth rate (CAGR) of around 7.5% expected over the forecast period from 2023 to 2030. This market's growth
Actinium-225 Research:CAGR of 20.6% during the forecast period
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Actinium-225- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years. The global
Hematopoietic Stem Cell Transplantation Market to Expand Significantly by 2034, …
The Hematopoietic Stem Cell Transplantation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hematopoietic Stem Cell Transplantation pipeline products will significantly revolutionize the Hematopoietic Stem Cell Transplantation market dynamics. DelveInsight's "Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hematopoietic Stem Cell Transplantation, historical and forecasted epidemiology as
Actinium-225 Market: Size, Share, Growth, Analysis, Key Players, Revenue, | Valu …
Actinium-225 Market Size The global Actinium-225 market was valued at US$ 0.6 million in 2023 and is anticipated to reach US$ 1.6 million by 2030, witnessing a CAGR of 15.2% during the forecast period 2024-2030. View sample report https://reports.valuates.com/request/sample/QYRE-Auto-35M13954/Global_Actinium_225_Market_Research_Report_2023 Actinium-225 Market Actinium-225 (225Ac, Ac-225) is an isotope of actinium. It undergoes alpha decay to francium-221 with a half-life of 10 days, and is an intermediate decay product in the neptunium series (the decay chain starting
Hematopoietic Stem Cell Transplantation Market Growth to Accelerate in Forecast …
The Hematopoietic Stem Cell Transplantation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hematopoietic Stem Cell Transplantation pipeline products will significantly revolutionize the Hematopoietic Stem Cell Transplantation market dynamics. DelveInsight's "Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hematopoietic Stem Cell Transplantation, historical and forecasted epidemiology as well as